mecamylamine hydrochloride

Also found in: Dictionary.

mec·a·myl·a·mine hy·dro·chlor·ide

(mek-ă-mil'ă-mēn hīdrō-klōr'īd),

A secondary amine that blocks transmission of impulses at autonomic ganglia (similar to but more effective than hexamethonium).

mecamylamine hydrochloride

[mek′əmil′əmēn]

a ganglionic blocking agent (antihypertensive).

indication It is prescribed in the management of severe essential hypertension and uncomplicated malignant hypertension.

contraindications Coronary or cerebrovascular insufficiency, recent myocardial infarction, uremia, pyelonephritis, glaucoma, or known hypersensitivity to this drug prohibits its use.

adverse effects Among the most serious adverse effects are orthostatic hypotension, paralytic ileus, urinary retention, and cycloplegia. The incidence of side effects is very high because the drug reduces all autonomic activity.

mecamylamine hydrochloride

(mĕk″ă-mĭl′ă-mĭn)

An antihypertensive of the ganglionic blocking agent type.

Mentioned in ?

Inversine

References in periodicals archive ?

In addition, we believe that the results of our Phase II clinical trial of mecamylamine hydrochloride as an augmentation therapy for major depression and the preclinical profile of TC-5214, an enantiomer of mecamylamine, bode well for the potential of TC-5214 and look forward to its expected entry into the clinic in the first quarter of 2008.

Confirmed plans to develop TC-5214, the S+ enantiomer of mecamylamine hydrochloride, as an augmentation treatment for major depression and expect to initiate clinical development in the first quarter of 2008;

Targacept Reports Third Quarter 2007 Financial Results

NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced plans to advance TC-5214, one of two enantiomers of mecamylamine hydrochloride, into clinical development as an augmentation therapy for patients who are inadequate responders to first-line antidepressant treatments.

Mecamylamine hydrochloride is a racemic compound comprised of two mirror image halves known as the S+ and R- enantiomers.

Targacept Announces Plans to Develop Enantiomer of Mecamylamine as Augmentation Therapy for Depression

The data suggest that an add-on treatment of mecamylamine hydrochloride, a broad spectrum nicotinic antagonist, improved symptoms of depression in patients who were inadequate responders to first-line citalopram therapy.

Targacept Presents Data from TRIDMAC(TM) Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients